Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™

The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS) Ii-Key-SARS-CoV-2

Read more

Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand

Memorandum of Understanding (MOU) signed by both parties Negotiating final contract terms Upfront payment on closing Licensing fees, expenses, and

Read more

Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program

Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of

Read more

NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets

Bintai Kinden Corporation Berhad (www.bintai.com.my), an investment holding company headquartered in Malaysia will fund the U.S. Clinical Trials for the

Read more

NuGenerex Immuno-Oncology Announces Shareholder Conference Call on Thursday August 27th, 2020 at 9:30 AM to Provide Details on Impending Corporate Initiatives

Ii-Key-SARS-CoV-2 vaccine progress Ii-Key-H1 Swine flu vaccine opportunity SEC Filings and plans for listing on a national exchange MIRAMAR, Fla.,

Read more